PharmaShots Weekly Snapshot (November 04-08, 2019)

Share this

PharmaShots Weekly Snapshot (November 04-08, 2019)

?1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma

Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell Lymphoma

??2. Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease

Published: Nov 07, 2019 | Tags: Janssen, Reports, Submission, MAA, EMA, Ebola Vaccine Regimen, Prevent, Ebola Virus Disease

??3. Yuhan Pharmaceutical Collaborates with Cyclica to Enhance Drug Development Utilizing AI-Integrated Drug Discovery Platform

Published: Nov 07, 2019 | Tags: Yuhan Pharmaceutical, Collaborates, Cyclica, Enhance, Drug Development, Utilizing, AI-Integrated Drug Discovery Platform

?4. Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM4 Study as 1L Treatment for Multiple Myeloma Patients Not Treated with Stem Cell Transplantation

Published: Nov 07, 2019 | Tags: Takeda, Reports, Results, Ninlaro, ixazomib, P-III, TOURMALINE-MM4 Study, 1L, Treatment, Multiple Myeloma, Stem Cell Transplantation 

5. ?Sierra Oncology Amends its Asset Purchase Agreement with Gilead for Momelotinib Signed in 2018

Published: Nov 07, 2019 | Tags: Sierra Oncology, Amends, Asset Purchase Agreement, Gilead, Momelotinib, Signed, 2018

???6. AstraZeneca Reports Results of Roxadustat in P-III OLYMPUS and ROCKIES Studies for Chronic Kidney Disease Patients with Anaemia

Published: Nov 07, 2019 | Tags: AstraZeneca, Reports, Results, Roxadustat, P-III, OLYMPUS, ROCKIES, Studies, Chronic Kidney Disease, Anaemia

7. ?? Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan) in the US

Published: Nov 07, 2019 | Tags: Teva, Celltrion, Reports, Availability, Truxima, biosimilar, Rituxan, US

8. Bio Thera’s QLETLI (biosimilar, adalimumab) Receives NMPA’s Approval for Auto-Immune Diseases in China

Published:  Nov 07, 2019 | Tags: Bio Thera, QLETLI, biosimilar, adalimumab, Receives, NMPA, Approval, Auto-Immune Diseases, China

9. AstraZeneca to Invest $1B for the Transformation of Healthcare in China

Published: Nov 06, 2019 | Tags: AstraZeneca, Invest, $1B, Transformation, Healthcare, China

10. ?? STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

Published: Nov 07, 2019 | Tags: STADA, Signs, Exclusive, Commercialization Agreement, Alvotech, Seven, Biosimilars, Europe

11. ? Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014

Published: Nov 07, 2019 | Tags: Novo Nordisk, Signs, Exclusive, Worldwide, License Agreement, UBE Industries, UD-014

12. ?Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases

Published: Oct 24, 2019 | Tags: Novartis, Collaborates, Pliant Therapeutics, Develop, Therapies, NASH, Fibrotic Diseases

?13. ? Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda

Published: Nov 06, 2019 | Tags: Merck, Signs, Worldwide, Agreement, Promega, Develop, MSI Technology, CDx, Keytruda, pembrolizumab

?14. Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar of Lucentis (ranibizumab) in the US

Published: Nov 06, 2019 | Tags: Coherus, Signs, Exclusive, License Agreement, Bioeq, Biosimilar, Lucentis, ranibizumab, US

15. ?? Biogen Signs an Exclusive Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio

Published: Nov 06, 2019 | Tags: Biogen, Signs, Commercialization Agreement, Samsung Bioepis, Expand, Biosimilars Portfolio

16. ? Regeneron Signs a Research and Option to License Agreement with Vyriad for Oncolytic Virus-Based Therapies

Published: Nov 06, 2019 | Tags: Agreement, Oncolytic Virus-Based, Option To License, Regeneron, Research, Signs, Therapies, Vyriad

17. Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma Outside Japan

Published: Nov 06, 2019 | Tags: Eisai, Transfer, Royalty Rights, Royalty Pharma, Tazemetostat, Outside, Japan

18. ? Evotec Collaborates with Vifor Pharma to Launch a Joint Venture to Discover and Develop Therapies for Nephrology

Published: Nov 06, 2019 | Tags: Evotec,  Collaborates, Vifor Pharma, Launch, Joint Venture, Discover, Develop, Therapies, Nephrology

?19. Vela Diagnostics’ Sentosa SQ HIV-1 Genotyping Assay Receives the US FDA’s DE Novo Authorization for Detection of HIV-1 Genomic Drug Resistance Mutations (DRMs)

Published: Nov 05, 2019 | Tags: Vela Diagnostics, Sentosa SQ HIV-1 Genotyping Assay, Receives, US FDA, DE Novo Authorization, Detection, HIV-1 Genomic Drug Resistance Mutations, DRMs

20. ? BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer

Published: Nov 05, 2019 | Tags: BioLineRx, Reports, Results, BL-8040, Combination, Keytruda, pembrolizumab, P-IIb Trial, Patients, Metastatic Pancreatic Cancer

21. ?? Takeda Signs an Exclusive License and Research Agreement with MD Anderson for CAR NK Cell Therapies

Published: Nov 05, 2019 | Tags: Takeda, Signs, Exclusive, License, Research, Agreement, MD Anderson, CAR NK Cell, Therapies

?22. BeiGene Signs an Exclusive Worldwide License Agreement with Seattle Genetics to Advance Preclinical Candidates Treating Cancer

Published: Nov 06, 2019 | Tags: BeiGene, Signs, Exclusive, Worldwide, License, Agreement, Seattle Genetics, Advance, Preclinical, Candidates, Treating, Cancer

23. ? Stryker to Acquire Wright Medical for $5.4B

Published: Nov 04, 2019 | Tags: Stryker, Acquire, Wright Medical, $5.4B

24. ? Henlius and Ascentage Pharma Collaborate to Evaluate the Combination Therapy for Chronic Lymphocytic Leukemia in China

Published: Nov 04, 2019 | Tags:  Henlius, Ascentage Pharma, Collaborate, Evaluate, Combination Therapy, Chronic Lymphocytic Leukemia, China

25. ?? Sanofi’s Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA’s Approval for Adults Aged= 65yrs.

Published: Nov 04, 2019 | Tags: Sanofi, Fluzone, High-Dose Quadrivalent, Influenza Vaccine, Receives, FDA, Approval, Adults, Aged= 65yrs.

26. ? Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to STADA for ~$660M

Published: Nov 05, 2019 | Tags: Takeda, Divest, Portfolio, Select OTC, Non-Core Assets, STADA, $660M

27. ? Sandoz’s Ziextenzo (biosimilar, pegfilgrastim) Receives the US FDA’s Approval to Decrease the Incidence of Febrile Neutropenia

Published: Nov 05, 2019 | Tags: Sandoz, Ziextenzo, biosimilar, pegfilgrastim, Receives, US, FDA, Approval, Decrease, Incidence of Febrile Neutropenia

28. Boehringer Ingelheim and Lilly Restructure their Alliance to Emphasis Full Expertise and Investment on Jardiance

Published: Nov 04, 2019 | Tags: Boehringer Ingelheim, Lilly, Modernize, Alliance, Emphasis, Full, Expertise, Investment, Jardiance

29. ? Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

Published: Nov 04, 2019 | Tags: Halozyme, Discontinue, P-III, HALO-301 Study, PEGPH20, Treatment, Metastatic Pancreatic Cancer

30. Yas Holding to Acquire Stake in Alvotech and Signs an Exclusive Agreement for its Three Biosimilar Candidates

Published: Nov 04, 2019 | Tags: Yas Holding, Acquire, Stake, Alvotech, Signs, Exclusive, Partnership, Three, Biosimilar Candidates

31. Janssen Collaborates with Vifor Pharma to Co-commercialize Invokana (canagliflozin) for the Treatment of Diabetic Kidney Disease in the US

Published: Nov 04, 2019 | Tags: Janssen, Collaborates, Vifor Pharma, Co-commercialize, Invokana, canagliflozin, Treat, Diabetic Kidney Disease, US

32. Sanofi Reports Results of Toujeo (insulin glargine 300 Units/mL) in P-III EDITION JUNIOR Study in Children and Adolescents with Type 1 Diabetes

Published: Nov 04, 2019 | Tags: Sanofi, Reports, Positive Results, Toujeo, insulin glargine, 300 Units/mL, P-III, EDITION JUNIOR, Study, Children, Adolescents, Type 1 Diabetes

33. Google to Acquire Fitbit for ~$2.1B

Published: Nov 01, 2019 | Tags: Google, Acquire, Fitbit, ~2.1B

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions